Patents by Inventor Yufang Xiao

Yufang Xiao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS
    Publication number: 20240025922
    Abstract: Tetrahydropyrido[3,4-d]pyrimidines compounds are provided that are potent HPK1 inhibitors. The compounds are useful to treat or prevent cancer and/or inflammatory and/or autoimmune diseases or symptoms thereof in mammals, particularly humans. The compounds have a chemical structure of the general Formula (I), (II), (III), (IV) or (V) or enantiomers or diastereomers or mixtures thereof or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: May 8, 2023
    Publication date: January 25, 2024
    Inventors: Momar TOURE, Bin LI, Constantin NEAGU, Yanping WANG, Theresa JOHNSON, Andrea UNZUE LOPEZ, Yufang XIAO, Emily FRIIS, Maria DIPOTO, Satenig GULER
  • Pyrimidinone derivatives as SHP2 antagonists
    Patent number: 11702392
    Abstract: The invention relates to pyrimidinone derivatives of the general Formula I, or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.
    Type: Grant
    Filed: February 22, 2021
    Date of Patent: July 18, 2023
    Assignee: Merck Patent GmbH
    Inventors: Catherine Jorand-Lebrun, Roch Boivin, Theresa Johnson, Yanping Wang, Yufang Xiao, Xiaoling Chen, Nina Linde, Doreen Musch, Deepak Kumar
  • PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
    Publication number: 20230019491
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKK? inhibitors.
    Type: Application
    Filed: October 17, 2018
    Publication date: January 19, 2023
    Inventors: Srinivasa R. Karra, Yufang XIAO, Brian Sherer
  • Pyrimidine TBK/IKKe inhibitor compounds and uses thereof
    Patent number: 11440899
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKK? inhibitors.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: September 13, 2022
    Assignee: Merck Patent GmbH
    Inventors: Srinivasa R. Karra, Yufang Xiao, Brian Sherer, Eugene Checkler
  • PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
    Publication number: 20210214339
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKK? inhibitors.
    Type: Application
    Filed: October 17, 2018
    Publication date: July 15, 2021
    Inventors: Srinivasa R. KARRA, Yufang XIAO, Brian SHERER, Eugene CHECKLER
  • PYRIMIDINONE DERIVATIVES AS SHP2 ANTAGONISTS
    Publication number: 20210179565
    Abstract: The invention relates to pyrimidinone derivatives of the general Formula I, or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.
    Type: Application
    Filed: February 22, 2021
    Publication date: June 17, 2021
    Inventors: Catherine JORAND-LEBRUN, Roch BOIVIN, Theresa JOHNSON, Yanping WANG, Yufang XIAO, Xiaoling CHEN, Nina LINDE, Doreen MUSCH, Deepak KUMAR
  • Pyrimidinone derivatives as SHP2 antagonists
    Patent number: 11001561
    Abstract: The invention relates to pyrimidinone derivatives of the general Formula I, or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: May 11, 2021
    Assignee: Merck Patent GmbH
    Inventors: Catherine Jorand-Lebrun, Roch Boivin, Theresa Johnson, Yanping Wang, Yufang Xiao, Xiaoling Chen, Nina Linde, Doreen Musch, Deepak Kumar
  • GCN2 inhibitors and uses thereof
    Patent number: 10988477
    Abstract: The present invention provides compounds inhibiting General amino acid Control Non-derepressible 2 kinase (“GCN2”), compositions thereof, and methods of using the same for treating various disorders, such as cancer.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: April 27, 2021
    Assignees: Merck Patent GmbH, Vertex Pharmaceuticals Incorporated
    Inventors: Andrew Bayly, Matthew Bleich, Jean-Damien Charrier, James Dodd, Steven Durrant, Meredith Suzanne Eno, Gorka Etxebarria I Jardi, Simon Everitt, Damien Fraysse, Shazia Kelly, Ronald Knegtel, Igor Mochalkin, Michael Mortimore, Kiri North, Filippos Porichis, Robert Pullin, Alistair Rutherford, Pierre-Henri Storck, Heather Clare Twin, Yufang Xiao
  • GCN2 INHIBITORS AND USES THEREOF
    Publication number: 20210040083
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: June 22, 2020
    Publication date: February 11, 2021
    Inventors: Matthew Bleich, Jean-Damien Charrier, Huijun Dong, Steven Durrant, Meredith Suzanne Eno, Gorka Etxebarria I Jardi, Simon Everitt, Damien Fraysse, Ronald Knegtel, Igor Mochalkin, Kiri North, Filippos Porichis, Hui Qiu, Robert Pullin, Pierre-Henri Storck, Heather Clare Twin, Yufang Xiao
  • PYRIMIDINONE DERIVATIVES AS SHP2 ANTAGONISTS
    Publication number: 20200317622
    Abstract: The invention relates to pyrimidinone derivatives of the general Formula I, or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.
    Type: Application
    Filed: April 8, 2020
    Publication date: October 8, 2020
    Inventors: Catherine Jorand-Lebrun, Roch Boivin, Theresa Johnson, Yanping Wang, Yufang Xiao, Xiaoling Chen, Nina Linde, Doreen Musch, Deepak Kumar
  • GCN2 inhibitors and uses thereof
    Patent number: 10793563
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: October 6, 2020
    Assignees: MERCK PATENT GMBH, VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Matthew Bleich, Jean-Damien Charrier, Huijun Dong, Steven Durrant, Meredith Suzanne Eno, Gorka Etxebarria I Jardi, Simon Everitt, Damien Fraysse, Ronald Knegtel, Igor Mochalkin, Kiri North, Filippos Porichis, Hui Qiu, Robert Pullin, Pierre-Henri Storck, Heather Clare Twin, Yufang Xiao
  • TBK/IKK inhibitor compounds and uses thereof
    Patent number: 10428080
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKK? inhibitors.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: October 1, 2019
    Assignee: Merck Patent GmbH
    Inventors: Brian A. Sherer, Srinivasa Karra, Yufang Xiao
  • GCN2 INHIBITORS AND USES THEREOF
    Publication number: 20190233425
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: January 28, 2019
    Publication date: August 1, 2019
    Inventors: Andrew Bayly, Matthew Bleich, Jean-Damien Charrier, James Dodd, Steven Durrant, Meredith Suzanne Eno, Gorka Etxebarria I Jardi, Simon Everitt, Damien Fraysse, Shazia Kelly, Ronald Knegtel, Igor Mochalkin, Michael Mortimore, Kiri North, Filippos Porichis, Robert Pullin, Alistair Rutherford, Pierre-Henri Storck, Heather Clare Twin, Yufang Xiao
  • GCN2 INHIBITORS AND USES THEREOF
    Publication number: 20190233411
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: January 28, 2019
    Publication date: August 1, 2019
    Inventors: Matthew Bleich, Jean-Damien Charrier, Huijun Dong, Steven Durrant, Meredith Suzanne Eno, Gorka Etxebarria I Jardi, Simon Everitt, Damien Fraysse, Ronald Knegtel, Igor Mochalkin, Kiri North, Filippos Porichis, Hui Qiu, Robert Pullin, Pierre-Henri Storck, Heather Clare Twin, Yufang Xiao
  • Heterocyclic derivatives as modulators of kinase activity
    Patent number: 10287300
    Abstract: The invention provides novel imidazol-piperidinyl derivatives of the formula (I) in which R1, R2, W, X1, X2, X3, X4 and n have the meanings indicated in formula I, and their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: May 14, 2019
    Assignee: Merck Patent GmbH
    Inventors: Ruoxi Lan, Bayard R. Huck, Xiaoling Chen, Yufang Xiao
  • Cyclic amine azaheterocyclic carboxamides
    Patent number: 10087166
    Abstract: The invention provides novel cyclic amine azaheterocyclic carboxamide according to Formula (I), Formula (II) and Formula (III) their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: October 2, 2018
    Assignee: Merck Patent GmbH
    Inventors: Bayard R. Huck, Xiaoling Chen, Constantin Neagu, Reinaldo Jones, Yufang Xiao, Igor Mochalkin
  • Heterocyclic carboxamides as modulators of kinase activity
    Patent number: 10080753
    Abstract: The invention provides novel heterocyclic carboxamide compounds according to Formula (I) their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: September 25, 2018
    Assignee: Merck Patent GmbH
    Inventors: Bayard R. Huck, Xiaoling Chen, Yufang Xiao, Ruoxi Lan, Lizbeth Celeste De Selm, Constantin Neagu, Justin Potnick, Srinivasa R. Karra, Theresa L Johnson
  • Aminopyrimidine derivatives for use as modulators of kinase activity
    Patent number: 10080750
    Abstract: The invention provides novel heterocyclic amine compounds according to Formula (I) and their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: September 25, 2018
    Assignee: Merck Patent GmbH
    Inventors: Ruoxi Lan, Bayard R. Huck, Xiaoling Chen, Lizbeth C. Deselm, Hui Qiu, Yufang Xiao, Constantin Neagu, Igor Mochalkin, Theresa L. Johnson
  • TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF
    Publication number: 20180244682
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKK? inhibitors.
    Type: Application
    Filed: April 26, 2018
    Publication date: August 30, 2018
    Inventors: Brian A. SHERER, Srinivasa KARRA, Yufang XIAO
  • TBK/IKK inhibitor compounds and uses thereof
    Patent number: 9988391
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKK? inhibitors.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: June 5, 2018
    Assignee: Merck Patent GmbH
    Inventors: Brian A. Sherer, Srinivasa Karra, Yufang Xiao